TY  - JOUR
A1  - Eichler, Martin
A1  - Pink, Daniel
A1  - Menge, Franka
A1  - Jakob, Jens
A1  - Hentschel, Ludwig Leopold
A1  - Richter, Stephan
A1  - Hohenberger, Peter
A1  - Kasper, Bernd
A1  - Andreou, Dimosthenis
A1  - Singer, Susanne
A1  - Grützmann, Robert
A1  - Dmytrow, Diana I.
A1  - Arndt, Karin
A1  - Tuchscherer, Armin
A1  - Reichardt, Peter
A1  - Ahrens, Marit
A1  - Kunitz, Annegret
A1  - Mohm, Johannes
A1  - Bornhäuser, Martin
A1  - Schmitt, Jochen Maximilian
A1  - Schuler, Markus Kajo
T1  - Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: cross-sectional results of a German multicentre observational study (PROSa)
T2  - European journal of cancer care
N2  - Objective. We investigated the health-related quality of life (HRQoL) of patients with gastrointestinal stromal tumours (GIST). Methods: In the multicentre PROSa study, the HRQoL of adult GIST patients was assessed between 2017 and 2019 using the European Organisation for Research and Treatment of Cancer HRQoL questionnaire (EORTC QLQ-C30). We performed group comparisons and multivariate linear regressions. Results: Among 130 patients from 13 centres, the mean global HRQoL was 63.3 out of 100 points. Higher sores indicate better HRQoL. The highest restrictions were in emotional, social, role functioning, insomnia, fatigue, and pain. In multivariate linear regression, we found no significant differences between patients receiving tyrosine kinase inhibitor (TKI) treatment and those without TKI treatment as well as between patients treated with curative or with palliative intent. Patients who received multiple lines of TKI treatment had the most restrictions, notably in physical (unstandardized regression coefficient [B] = −15.7), role (B = −25.7), social (B = −18.4), and cognitive functioning (B = −19.7); fatigue (B = 15.93); general health (B = −14.23); and EORTC-sum score (B = −13.82) compared to all other patients. Conclusion: The highest HRQoL restrictions were in GIST patients receiving multiple lines of TKI therapy. Underlying causes need further investigation.
KW  - clinically important restrictions and symptoms
KW  - gastrointestinal stromal tumours
KW  - health-relatedquality of life
KW  - observational study
KW  - rare disease
KW  - tyrosine kinase inhibitors
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63961
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-639616
SN  - 1365-2354
N1  - The PROSa study was funded by the German Cancer Aid (No. 111713).
VL  - 30
IS  - 6, art. e13484
SP  - 1
EP  - 15
PB  - Wiley-Blackwell
CY  - Oxford [u.a.]
ER  -